Scandinavian ChemoTech AB Class B (NEEMS.B) AI Stock Analysis

Scandinavian ChemoTech AB Class B

(Nasdaq OMX AB:NEEMS.B)

Select Model

Rating:45Neutral

Price Target:SEK 2.00▼(-10.71% Downside)

Action:reiterated

Date:10/28/26

The score is held down mainly by ongoing losses and negative free cash flow despite strong revenue growth and improved gross margin. Technicals add further pressure given the stock’s downtrend and negative MACD. A debt-free balance sheet provides some stability, but the negative P/E underscores that profitability is not yet established.

Positive Factors

Strong Revenue GrowthRapid TTM revenue expansion indicates growing commercial activity and increasing adoption of the company’s offerings. If this trajectory persists, a larger revenue base could improve operating leverage, support broader market reach, and provide a foundation for eventual profitability.

Negative Factors

Persistent UnprofitabilityDespite strong revenue growth and improved gross margin, operating costs continue to exceed gross profit, leaving the company deeply loss-making. Persistent negative earnings weaken internal funding capacity and make the durability of growth dependent on achieving further cost control and scale.

Scandinavian ChemoTech AB Class B (NEEMS.B) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 58.72M
Dividend Yield: ―
Average Volume (3M): 16.65K
Price to Earnings (P/E): -14.5
Beta (1Y): -0.74
Revenue Growth: 3.73%
EPS Growth: 16.13%
Country: Sweden
Employees: 1
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Scandinavian ChemoTech AB Class B Business Overview & Revenue Model

Company Description

Neem's Hill AB, a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. It offers IQwave, an electroporation that generates tumor-specific electrica...

Scandinavian ChemoTech AB Class B Financial Statement Overview

Summary

Revenue growth is very strong in TTM (~265%) and gross margin improved materially to ~53%, but the company remains deeply unprofitable (operating and net losses; ~-50% net margin) with ongoing negative operating cash flow and free cash flow. A debt-free balance sheet helps, yet equity has eroded over time, reflecting the durability risk if losses persist.

Income Statement

28Negative

Balance Sheet

52Neutral

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	12.61M	12.29M	6.57M	2.82M	473.00K	49.00K
Gross Profit	6.64M	-4.50M	4.78M	1.66M	-55.00K	323.00K
EBITDA	-3.27M	-4.33M	-12.38M	-19.58M	-20.81M	-17.03M
Net Income	-6.31M	-8.06M	-13.72M	-21.09M	-22.75M	-17.74M
Balance Sheet
Total Assets	11.11M	13.20M	13.38M	14.87M	21.70M	25.81M
Cash, Cash Equivalents and Short-Term Investments	1.46M	3.67M	949.00K	923.00K	5.85M	8.68M
Total Debt	0	0	0	0	0	53.00K
Total Liabilities	9.47M	10.01M	7.40M	3.84M	7.71M	1.89M
Stockholders Equity	1.64M	3.19M	5.98M	11.03M	13.99M	23.92M
Cash Flow
Free Cash Flow	-3.78M	-4.18M	-13.19M	-18.91M	-19.96M	-22.36M
Operating Cash Flow	-3.65M	-3.75M	-13.14M	-18.23M	-19.63M	-19.18M
Investing Cash Flow	-502.00K	-426.00K	-2,000	-468.00K	-603.00K	-3.33M
Financing Cash Flow	4.59M	6.89M	13.17M	13.77M	17.26M	29.71M

Scandinavian ChemoTech AB Class B Technical Analysis

Technical Analysis SentimentNegative

Last Price2.24

Price Trends

50DMA2.67Negative

100DMA3.06Negative

200DMA3.38Negative

Market Momentum

MACD-0.14Positive

RSI41.33Neutral

STOCH43.20Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NEEMS.B, the sentiment is Negative. The current price of 2.24 is below the 20-day moving average (MA) of 2.47, below the 50-day MA of 2.67, and below the 200-day MA of 3.38, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 41.33 is Neutral, neither overbought nor oversold. The STOCH value of 43.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NEEMS.B.

Scandinavian ChemoTech AB Class B Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:NEEMS.B against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	70Outperform	SEK 451.68M	2.35	63.09%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ISOFOL	49Neutral	SEK 383.95M	-5.99	-54.41%	―	―	32.79%
SE:ELIC	48Neutral	SEK 177.19M	-7.51	-56.09%	―	―	14.10%
SE:ONCO	47Neutral	SEK 721.66M	-2.14	―	―	87.23%	35.27%
SE:NEEMS.B	45Neutral	SEK 58.72M	-14.45	-190.99%	―	3.73%	16.13%
SE:IMMU	43Neutral	SEK 348.89M	-3.07	-18.05%	―	―	15.97%

* Healthcare Sector Average

Performance Comparison

SE:NEEMS.B and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:NEEMS.B	Scandinavian ChemoTech AB Class B	2.24	-3.16	-58.52%
SE:ONCO	Oncopeptides AB	1.67	-3.75	-69.16%
SE:ISOFOL	Isofol Medical AB	1.20	0.51	74.89%
SE:ELIC	Elicera Therapeutics AB	2.65	-3.44	-56.47%
SE:IMMU	Immunicum AB	5.50	-1.89	-25.58%
SE:CANTA	Cantargia AB	1.60	-1.97	-55.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

Scandinavian ChemoTech AB Class B AI Stock Analysis